FBM 5712
Alternative Names: FBM-5712Latest Information Update: 28 Jul 2025
At a glance
- Originator Thirona Bio
- Developer MannKind Corporation; Thirona Bio
- Class Antifibrotics; Small molecules
- Mechanism of Action Transforming growth factor beta receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis; Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in Fibrosis in USA (Topical)
- 28 Jul 2025 No recent reports of development identified for preclinical development in Fibrosis(Prevention) in USA (Topical)
- 28 Jul 2025 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in USA (Inhalation, Powder)